229 related articles for article (PubMed ID: 15848204)
1. Synthesis, biological studies and molecular modeling investigation of 1,3-dimethyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as potential adenosine receptor antagonists.
Pastorin G; Bolcato C; Cacciari B; Kachler S; Klotz KN; Montopoli C; Moro S; Spalluto G
Farmaco; 2005 Apr; 60(4):299-306. PubMed ID: 15848204
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, biological and modeling studies of 1,3-di-n-propyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as adenosine receptor antagonists.
Pastorin G; Bolcato C; Cacciari B; Kachler S; Klotz KN; Montopoli C; Moro S; Spalluto G
Farmaco; 2005 Aug; 60(8):643-51. PubMed ID: 15961085
[TBL] [Abstract][Full Text] [Related]
3. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.
Cheong SL; Dolzhenko A; Kachler S; Paoletta S; Federico S; Cacciari B; Dolzhenko A; Klotz KN; Moro S; Spalluto G; Pastorin G
J Med Chem; 2010 Apr; 53(8):3361-75. PubMed ID: 20307065
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
[TBL] [Abstract][Full Text] [Related]
5. 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
Minetti P; Tinti MO; Carminati P; Castorina M; Di Cesare MA; Di Serio S; Gallo G; Ghirardi O; Giorgi F; Giorgi L; Piersanti G; Bartoccini F; Tarzia G
J Med Chem; 2005 Nov; 48(22):6887-96. PubMed ID: 16250647
[TBL] [Abstract][Full Text] [Related]
6. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.
Pastorin G; Da Ros T; Spalluto G; Deflorian F; Moro S; Cacciari B; Baraldi PG; Gessi S; Varani K; Borea PA
J Med Chem; 2003 Sep; 46(20):4287-96. PubMed ID: 13678407
[TBL] [Abstract][Full Text] [Related]
7. Selective human adenosine A3 antagonists based on pyrido[2,1-f]purine-2,4-diones: novel features of hA3 antagonist binding.
Priego EM; Pérez-Pérez MJ; von Frijtag Drabbe Kuenzel JK; de Vries H; Ijzerman AP; Camarasa MJ; Martín-Santamaría S
ChemMedChem; 2008 Jan; 3(1):111-9. PubMed ID: 18000937
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.
Pastorin G; Da Ros T; Bolcato C; Montopoli C; Moro S; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
J Med Chem; 2006 Mar; 49(5):1720-9. PubMed ID: 16509587
[TBL] [Abstract][Full Text] [Related]
9. QSAR of adenosine receptor antagonists. Part 3: Exploring physicochemical requirements for selective binding of 1,2,4-triazolo[5,1-i]purine derivatives with human adenosine A3 receptor subtype.
Roy K; Leonard JT; Sengupta C
Bioorg Med Chem Lett; 2004 Jul; 14(14):3705-9. PubMed ID: 15203147
[TBL] [Abstract][Full Text] [Related]
10. Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Colotta V; Lenzi O; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Traini C; Pedata F; Morizzo E; Moro S
J Med Chem; 2009 Apr; 52(8):2407-19. PubMed ID: 19301821
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists.
Baraldi PG; Cacciari B; Spalluto G; Bergonzoni M; Dionisotti S; Ongini E; Varani K; Borea PA
J Med Chem; 1998 Jun; 41(12):2126-33. PubMed ID: 9622554
[TBL] [Abstract][Full Text] [Related]
12. 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists.
Chang LC; Spanjersberg RF; von Frijtag Drabbe Künzel JK; Mulder-Krieger T; Brussee J; Ijzerman AP
J Med Chem; 2006 May; 49(10):2861-7. PubMed ID: 16686529
[TBL] [Abstract][Full Text] [Related]
13. New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists.
Baraldi PG; Preti D; Tabrizi MA; Fruttarolo F; Romagnoli R; Zaid NA; Moorman AR; Merighi S; Varani K; Borea PA
J Med Chem; 2005 Jul; 48(14):4697-701. PubMed ID: 16000006
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists.
Müller CE; Geis U; Hipp J; Schobert U; Frobenius W; Pawłowski M; Suzuki F; Sandoval-Ramírez J
J Med Chem; 1997 Dec; 40(26):4396-405. PubMed ID: 9435909
[TBL] [Abstract][Full Text] [Related]
15. 1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.
Catarzi D; Colotta V; Varano F; Lenzi O; Filacchioni G; Trincavelli L; Martini C; Montopoli C; Moro S
J Med Chem; 2005 Dec; 48(25):7932-45. PubMed ID: 16335918
[TBL] [Abstract][Full Text] [Related]
16. 5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists.
Da Settimo F; Primofiore G; Taliani S; Marini AM; La Motta C; Simorini F; Salerno S; Sergianni V; Tuccinardi T; Martinelli A; Cosimelli B; Greco G; Novellino E; Ciampi O; Trincavelli ML; Martini C
J Med Chem; 2007 Nov; 50(23):5676-84. PubMed ID: 17927167
[TBL] [Abstract][Full Text] [Related]
17. 1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.
Colotta V; Catarzi D; Varano F; Calabri FR; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Deflorian F; Moro S
J Med Chem; 2004 Jul; 47(14):3580-90. PubMed ID: 15214785
[TBL] [Abstract][Full Text] [Related]
18. Phenylethyl-substituted pyrimido[2,1-f]purinediones and related compounds: structure-activity relationships as adenosine A(1) and A(2A) receptor ligands.
Drabczyńska A; Müller CE; Schiedel A; Schumacher B; Karolak-Wojciechowska J; Fruziński A; Zobnina W; Yuzlenko O; Kieć-Kononowicz K
Bioorg Med Chem; 2007 Nov; 15(22):6956-74. PubMed ID: 17827019
[TBL] [Abstract][Full Text] [Related]
19. 4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Lenzi O; Colotta V; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Varani K; Marighetti F; Morizzo E; Moro S
J Med Chem; 2006 Jun; 49(13):3916-25. PubMed ID: 16789747
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological activity of tricyclic cycloalkylimidazo-, pyrimido- and diazepinopurinediones.
Drabczyńska A; Yuzlenko O; Köse M; Paskaleva M; Schiedel AC; Karolak-Wojciechowska J; Handzlik J; Karcz T; Kuder K; Müller CE; Kieć-Kononowicz K
Eur J Med Chem; 2011 Sep; 46(9):3590-607. PubMed ID: 21664729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
